Novartis’s Capmatinib Shows High Response Rates In NSCLC

AACR Lung Cancer Plenary Also Included Spectrum’s Poziotinib

 
• By Mandy Jackson
  
lung illustration
Phase II capmatinib and poziotinib data were presented at AACR

More from Clinical Trials

More from R&D